Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1800 results
December 2016
-
Media ReleaseNovartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec®ENESTop post-hoc analysis provides further insights into Treatment-free Remission (TFR) among Ph+ CML switch patients[1] The Tasigna TFR trials, including ENESTop, demonstrate our continued…
-
Media ReleaseNovartis survey uncovers real-world burden of myeloproliferative neoplasms (rare blood cancers) on daily activity and ability to workFindings across six countries and four continents showed a reduction in quality of life for majority (71%) of patients living with myeloproliferative neoplasms (MPNs)[1] Patients…
-
Media ReleaseNew interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference productASSIST-FL trial demonstrates equivalent safety, efficacy, pharmacokinetics and pharmacodynamics of Sandoz proposed biosimilar rituximab (GP2013) to the reference product[1] Interim data in over…
-
Media ReleaseNovartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL82% (41 of 50) of patients achieved complete remission or complete remission with incomplete blood count recovery in interim analysis of Novartis study (ELIANA) ELIANA, the first global CAR T…
-
Media ReleaseNovartis SEG101 (crizanlizumab, formerly SelG1) significantly reduces frequency of sickle cell pain crises in Phase II studySEG101 reduced annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo in patients with or without hydroxyurea therapy SEG101 is a potential new disease-…
-
How Zika infects the growing brain
The fast-spreading virus can take multiple routes into developing human nerve cells.
-
Killing three diseases with one stone in the lab
Novartis researchers have discovered a compound that is showing promise against three parasites that cause three neglected diseases.
November 2016
-
In The NewsNew strategies for improving access in lower-income countriesHumanosphere highlights the work Novartis Access is doing to find a social enterprise solution to help patients in lower-income countries get access to medicines for chronic diseases.
-
Women in Science: Lilli Petruzzelli
A lung cancer researcher describes her journey toward a career in science at Novartis.
-
Media ReleaseNovartis Access communique son bilan à un an et annonce la signature d'un protocole d'accord avec le RwandaLe Rwanda devient le troisième pays à lancer Novartis Access, un programme de distribution de médicaments pour traiter les maladies chroniques dans les pays à faible revenu. Les premières livraisons…
-
Media ReleaseNovartis Access shares one-year learnings and announces memorandum of understanding with RwandaRwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017 Since September 2015, Novartis Access has delivered more than…
-
Media ReleaseNovartis Access informiert über Erfahrungen im ersten Jahr und gibt Memorandum of Understanding mit Ruanda bekanntRuanda ist das dritte Land, welches das Portfolio von Novartis Access gegen chronische Krankheiten einführen wird. Die ersten Medikamentenlieferungen sind für Anfang 2017 geplant. Seit September…
Pagination
- ‹ Previous page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- …
- 150
- › Next page